Improved disease activity with fosdagrocorat (PF-04171327), a partial agonist of the glucocorticoid receptor, in patients with rheumatoid arthritis: a Phase 2 randomized study.

The differences in cortisol suppression between fosdagrocorat doses and both placebo and prednisone 5 mg were highly significant at both weeks 1 and 2 (all P < 0.001).

also in 132,142 other papers

14%, respectively), but these differences did not reach statistical significance.

also in 111,027 other papers